{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:22:55Z","timestamp":1791235375332,"version":"4.1.0"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.1001\/jamapsychiatry.2018.4489","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T19:59:38Z","timestamp":1550692778000},"page":"508","source":"Crossref","is-referenced-by-count":48,"title":["Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients With Schizophrenia"],"prefix":"10.1001","volume":"76","author":[{"given":"T. Scott","family":"Stroup","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Columbia University Irving Medical Center and New York State Psychiatric Institute, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Gerhard","sequence":"additional","affiliation":[{"name":"Institute for Health, Health Care Policy, and Aging Research, Rutgers University, New Brunswick, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Crystal","sequence":"additional","affiliation":[{"name":"Institute for Health, Health Care Policy, and Aging Research, Rutgers University, New Brunswick, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Huang","sequence":"additional","affiliation":[{"name":"Institute for Health, Health Care Policy, and Aging Research, Rutgers University, New Brunswick, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Statistics and Biostatistics, Rutgers University, Piscataway, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie M.","family":"Wall","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Columbia University Irving Medical Center and New York State Psychiatric Institute, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chacku","family":"Mathai","sequence":"additional","affiliation":[{"name":"Mental Health Association of Rochester, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Olfson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Columbia University Irving Medical Center and New York State Psychiatric Institute, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"yoi180113r1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr Bull"},{"issue":"7","key":"yoi180113r2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1001\/jamapsychiatry.2017.0624","article-title":"Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence.","volume":"74","author":"Correll","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"yoi180113r3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/YCO.0b013e32835d9efb","article-title":"Polypharmacy for schizophrenia.","volume":"26","author":"Ballon","year":"2013","journal-title":"Curr Opin Psychiatry"},{"issue":"6","key":"yoi180113r4","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1176\/appi.ajp.2015.15050618","article-title":"Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study.","volume":"173","author":"Tiihonen","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"5","key":"yoi180113r5","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1001\/archgenpsychiatry.2011.1532","article-title":"Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia.","volume":"69","author":"Tiihonen","year":"2012","journal-title":"Arch Gen Psychiatry"},{"issue":"10","key":"yoi180113r6","first-page":"CD003834","article-title":"Lithium for schizophrenia.","author":"Leucht","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"yoi180113r7","first-page":"CD004028","article-title":"Valproate for schizophrenia.","author":"Schwarz","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"yoi180113r8","first-page":"CD001258","article-title":"Carbamazepine for schizophrenia.","author":"Leucht","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"yoi180113r9","first-page":"CD005962","article-title":"Lamotrigine for schizophrenia.","author":"Premkumar","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"yoi180113r10","first-page":"CD006391","article-title":"Benzodiazepines for schizophrenia.","author":"Volz","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"yoi180113r11","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1176\/appi.ajp.2016.15081035","article-title":"Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis.","volume":"173","author":"Helfer","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"3","key":"yoi180113r12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/acps.2018.137.issue-3","article-title":"Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia.","volume":"137","author":"Galling","year":"2018","journal-title":"Acta Psychiatr Scand"},{"issue":"7","key":"yoi180113r13","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1017\/S1461145712000399","article-title":"Critical review of antipsychotic polypharmacy in the treatment of schizophrenia.","volume":"17","author":"Fleischhacker","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"yoi180113r14","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/schbul\/sbn018","article-title":"Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials.","volume":"35","author":"Correll","year":"2009","journal-title":"Schizophr Bull"},{"issue":"9","key":"yoi180113r15","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs.","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"issue":"8","key":"yoi180113r16","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1176\/ps.2010.61.8.830","article-title":"Health insurance coverage among persons with schizophrenia in the United States.","volume":"61","author":"Khaykin","year":"2010","journal-title":"Psychiatr Serv"},{"issue":"1","key":"yoi180113r17","first-page":"31","article-title":"Partial compliance with antipsychotics increases mental health hospitalizations in schizophrenic patients: analysis of a national managed care database.","volume":"2","author":"Kozma","year":"2009","journal-title":"Am Health Drug Benefits"},{"issue":"1-3","key":"yoi180113r18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.schres.2007.11.034","article-title":"The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.","volume":"100","author":"Swartz","year":"2008","journal-title":"Schizophr Res"},{"issue":"7","key":"yoi180113r19","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1176\/ps.2007.58.7.983","article-title":"Adding or switching antipsychotic medications in treatment-refractory schizophrenia.","volume":"58","author":"Kreyenbuhl","year":"2007","journal-title":"Psychiatr Serv"},{"issue":"1","key":"yoi180113r20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects.","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"yoi180113r21","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/biomet\/asq035","article-title":"Bounded, efficient, and doubly robust estimation with inverse weighting.","volume":"97","author":"Tan","year":"2010","journal-title":"Biometrika"},{"issue":"28","key":"yoi180113r22","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.v34.28","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"issue":"4","key":"yoi180113r23","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1198\/000313004X5824","article-title":"Model selection, confounder control, and marginal structural models: review and new applications.","volume":"58","author":"Joffe","year":"2004","journal-title":"Am Stat"},{"issue":"9896","key":"yoi180113r24","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"yoi180113r25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.seizure.2007.12.003","article-title":"Central nervous system adverse effects of new antiepileptic drugs: a meta-analysis of placebo-controlled studies.","volume":"17","author":"Zaccara","year":"2008","journal-title":"Seizure"},{"issue":"14","key":"yoi180113r26","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1001\/jama.2010.410","article-title":"Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death.","volume":"303","author":"Patorno","year":"2010","journal-title":"JAMA"},{"issue":"11","key":"yoi180113r27","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2165\/00023210-200822110-00002","article-title":"Pharmacological treatment of schizophrenia and co-occurring substance use disorders.","volume":"22","author":"Smelson","year":"2008","journal-title":"CNS Drugs"},{"issue":"10","key":"yoi180113r28","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1093\/oxfordjournals.aje.a117563","article-title":"Recall accuracy for prescription medications: self-report compared with database information.","volume":"142","author":"West","year":"1995","journal-title":"Am J Epidemiol"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamapsychiatry\/article-pdf\/76\/5\/508\/17528704\/jamapsychiatry_stroup_2019_oi_180113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T11:02:00Z","timestamp":1556708520000},"score":1,"resource":{"primary":{"URL":"http:\/\/archpsyc.jamanetwork.com\/article.aspx?doi=10.1001\/jamapsychiatry.2018.4489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.4489","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,1]]}}}